High prevalence of severe hypovitaminosis D in patients with advanced gastric cancer treated with first-line chemotherapy with or without anti-EGFR-directed monoclonal antibody (EXPAND trial) showing no prognostic impact
Jazyk angličtina Země Anglie, Velká Británie Médium print-electronic
Typ dokumentu klinické zkoušky, fáze III, časopisecké články, randomizované kontrolované studie, práce podpořená grantem
PubMed
31195354
DOI
10.1016/j.ejca.2019.05.011
PII: S0959-8049(19)30314-4
Knihovny.cz E-zdroje
- Klíčová slova
- 25-OHD plasma levels, Chemotherapy cetuximab, Gastric cancer, Prognosis, Vitamin D,
- MeSH
- adenokarcinom krev farmakoterapie mortalita MeSH
- capecitabinum terapeutické užití MeSH
- cetuximab terapeutické užití MeSH
- cisplatina terapeutické užití MeSH
- erbB receptory antagonisté a inhibitory MeSH
- humanizované monoklonální protilátky terapeutické užití MeSH
- lidé středního věku MeSH
- lidé MeSH
- nádory žaludku krev farmakoterapie mortalita MeSH
- nedostatek vitaminu D epidemiologie MeSH
- prevalence MeSH
- prognóza MeSH
- protokoly protinádorové kombinované chemoterapie terapeutické užití MeSH
- senioři MeSH
- vitamin D krev MeSH
- výsledek terapie MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky, fáze III MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
- Názvy látek
- capecitabinum MeSH
- cetuximab MeSH
- cisplatina MeSH
- EGFR protein, human MeSH Prohlížeč
- erbB receptory MeSH
- humanizované monoklonální protilátky MeSH
- vitamin D MeSH
PURPOSE: The goal of our analysis was to study pretherapeutic circulating 25-OHD plasma levels in patients with previously untreated advanced gastric cancer treated in the randomised controlled phase III Erbitux (cetuximab) in combination with Xeloda (capecitabine) and cisplatin in advanced esophago-gastric cancer (EXPAND) trial (NCT00678535) and to explore whether low 25-OHD plasma levels are associated with worse prognosis and may compromise the clinical efficacy of cetuximab. METHODS: Six hundred thirty patients with available pretherapeutic 25-OHD plasma levels and treated with chemotherapy based on capecitabine and cisplatin, or chemotherapy and cetuximab, were included. The Cox proportional hazard regression model was used to analyse the association between low 25-OHD and survival in both treatment arms. RESULTS: Majority of study patients were found to have severe vitamin D deficiency. No prognostic impact of 25-OHD plasma levels could be found in our patient cohort, and there was no indication of an interference of 25-OHD plasma levels and the efficacy of treatment with the anti-epidermal growth factor receptor monoclonal antibody cetuximab. CONCLUSIONS: Although majority of patients with advanced gastric cancer show hypovitaminosis D deficiency, there is no proof for a negative impact on survival or reduced treatment response. A prospective study is needed to investigate the potential benefit of vitamin D supplementation in this patient cohort during first-line chemotherapy.
Citace poskytuje Crossref.org
